A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

NCT00923247 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
22
Enrollment
NIH
Sponsor class

Stopped Terminated due to slow accrual,primary endpoint reached \& investigator left NIH.

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)